EUVIMEDAtklāt EUVIMED
Open access

Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study

Alaina Carr iD, Angela M Jenkins iD, Valeria Gómez iD, Janine Alexandria Lorenzo iD, Ryan Moclair iD, James Pocchia iD, Devansh Gandhi iD, Kristen Miller iD, Kristi D Graves iD, Jacqueline Jonklaas iD

JMIR Cancer · 2026

DOI: 10.2196/84151 ↗

At a glance

Journal article in JMIR Cancer, 2026. Written by Alaina Carr and 9 co-authors. Institution: Department of Oncology, Georgetown University Medical Center, Washington, DC, United States. Major MEDLINE topics: Thyroid Neoplasms, Iodine Radioisotopes. 48 references. The full text is freely available in PubMed Central.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Background

Thyroid cancer is often labeled a “good cancer” due to high survival rates. However, many patients diagnosed with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) experience short- and long-term symptoms as a result of treatment. These include salivary dysfunction, dry mouth, dry eyes, and nausea. Despite these challenges, patients report limited knowledge and unmet informational needs regarding RAI symptoms and symptom management. Evidence-based, patient-centered education to support symptom management during DTC survivorship is needed. Our team developed Radioactive Iodine Support (RAI Support), a prototype of a 4-week web-based intervention for RAI symptom management among survivors of DTC.

Objective

This study aimed to evaluate the usability of the RAI Support intervention among survivors of DTC who completed RAI treatment and assess preliminary effect sizes of change in RAI symptom burden, self-efficacy for managing chronic symptoms, informational needs, global physical and mental health, and health-related quality of life (HRQOL).

Methods

We conducted a longitudinal usability testing study with 8 participants over a 4-week period. At baseline (T1), participants completed an online survey and a 90-minute virtual usability testing session. During usability testing sessions, study staff used a think-aloud protocol to elicit feedback on the content, language, and visual appeal of the prototype across 5 tasks. Participants also completed the System Usability Scale (SUS). Participants were encouraged to continue using the intervention over the 4-week period, during which use data were recorded. A follow-up after assessment (T2) was completed at the end of the 4-week period of home use. Survey outcomes included RAI symptom burden, self-efficacy for managing chronic symptoms, informational needs, global physical and mental health, and HRQOL.

Results

Among the 8 survivors of DTC who had undergone RAI treatment (age: mean 45, SD 8.2 years), the mean SUS score was 88.1 (SD 8.7), indicating above-average usability. All participants effectively completed each task, with ease of use ranging from 100% to 87.5% and error rates ranging from 0% to 25%. Preliminary r effect size signals of change were found for improved self-efficacy, global mental health, and HRQOL (r values ranged from 0.31 to 0.45).

Conclusions

Survivors of DTC reported above-average usability of the RAI Support prototype and completed each task successfully. Variability in error rates and ease of use suggests that refinements are needed to further optimize usability and patient engagement. RAI Support also shows preliminary promise in improving self-efficacy for symptom management, global mental health, and HRQOL among survivors of DTC. Findings support future pilot testing.

Subjects

MeSH terms (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesHumansFemaleMaleMiddle AgedQuality of LifeAdultSymptom BurdenLongitudinal StudiesSurveys and QuestionnairesAgedPatient Education as Topic

Author keywords

internet-based interventioniodine radioisotopesself-efficacysurvivorshipsymptom burdenthyroid neoplasmsuser-centered design

Substances

Iodine Radioisotopes

Authors and institutions

  • Department of Oncology, Georgetown University Medical Center, Washington, DC, United States.
  • Department of Biology, College of Arts and Sciences, Georgetown University, Washington, DC, United States.
  • National Center for Human Factors in Healthcare, MedStar Health Research Institute, Washington, DC, United States.
  • Division of Endocrinology, Georgetown University, Washington, DC, United States.

ORCID profiles: Alaina Carr, Angela M Jenkins, Valeria Gómez, Janine Alexandria Lorenzo, Ryan Moclair, James Pocchia, Devansh Gandhi, Kristen Miller, Kristi D Graves, Jacqueline Jonklaas

Cite

APA

Carr, A., Jenkins, A. M., Gómez, V., Lorenzo, J. A., Moclair, R., Pocchia, J., Gandhi, D., Miller, K., Graves, K. D., & Jonklaas, J. (2026). Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study. JMIR Cancer. https://doi.org/10.2196/84151

Vancouver

Carr A, Jenkins AM, Gómez V, Lorenzo JA, Moclair R, Pocchia J, et al. Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study. JMIR Cancer. 2026. doi:10.2196/84151

BibTeX
@article{Carr2026,
  author = {Carr, Alaina and Jenkins, Angela M and Gómez, Valeria and Lorenzo, Janine Alexandria and Moclair, Ryan and Pocchia, James and Gandhi, Devansh and Miller, Kristen and Graves, Kristi D and Jonklaas, Jacqueline},
  title = {Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study},
  journal = {JMIR Cancer},
  year = {2026},
  doi = {10.2196/84151}
}
Start for free →